doravirine

FDA Drug Profile — PIFELTRO

doravirine is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including PIFELTRO. Available dosage form: tablet, film coated.

Drug details

Generic Name
doravirine
Brand Names
PIFELTRO
Application Number
NDA210806
Sponsor
Merck Sharp & Dohme LLC
NDC Codes
5
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
DORAVIRINE

Indications and Usage

1 INDICATIONS AND USAGE PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine [see Clinical Studies (14) ] . PIFELTRO, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.